The demand for IVF is surging globally.
getty
Conceivable Life Sciences has secured a $50 million Series A round to enhance its efforts in bringing AI-driven automation and advanced robotic precision to the In Vitro Fertilization (IVF) space. The funding round will be led by prominent investors including ARTIS Ventures, Stride, and ACME Ventures.
Currently, the IVF process involves a labor-intensive and manual workflow that relies heavily on human expertise, skill, and vision. This often results in inconsistencies in outcomes and variations in the experience for families undergoing this already challenging journey. The potential for errors adds significant stress; the average cost per IVF cycle in the United States ranges from $12,000 to $25,000, with many individuals requiring multiple cycles for a successful result. In addition to the financial burden, parents going through IVF must closely monitor their health and adhere to a strict medication regimen to optimize fertility. Therefore, any advancements that can streamline the process and improve consistency and success rates are highly valuable.
Conceivable aims to address these challenges by introducing its proprietary lab platform, Aura, which leverages AI algorithms and robotic technology to enhance precision throughout the entire IVF process, from dish preparation to embryo incubation.
The platform has already shown promising results, resulting in the birth of 18 healthy babies in an initial study. The company is currently conducting a larger study with 120 participants, expected to conclude by the end of the year. Conceivable plans to launch the product commercially early next year and utilize the funding to further its mission of supporting families and fertility.
Dr. Alejandro Chavez-Badiola, a reproductive endocrinologist and co-founder of Conceivable, emphasizes the importance of consistent outcomes and modern technology in fertility treatment. By integrating Aura into the IVF process, the aim is to make precision a standard practice.
The IVF industry is witnessing a surge in AI-driven innovations. Nova IVF recently introduced an AI-powered embryo assessment tool, while SpOvum Technologies is pioneering a new sperm injection technique. Additionally, various adjunctive solutions such as ovulation monitoring apps and fertility wearables are becoming popular in assisting families through the IVF journey. Conceivable distinguishes itself by offering a comprehensive platform that addresses every aspect of the workflow.
The increasing demand for fertility technologies and services underscores the need for disruption and innovation in the field. Research indicates that the global fertility market is projected to reach $87 billion by 2034, with a growing number of employees utilizing fertility benefits offered by companies. With nearly 40% of large employers providing these benefits, there is a significant opportunity for advancements that enhance patient experiences and societal health outcomes.
